Capricor climbs as FDA clears path for resubmission of cell therapy application

** Shares of therapy developer Capricor Therapeutics CAPR.O rise 1.6% to $6.29 premarket

** Co says it has completed a key clinical trial for its muscle disorder therapy and expects to share results by Q4

** Co says the U.S. FDA has agreed that data from the trial could be used to support its marketing application for the cell therapy, Deramiocel

** Deramiocel is being developed to treat Duchenne muscular dystrophy, a rare and progressive genetic disorder that causes muscle degeneration and weakness

** In July, the agency declined to approve Deramiocel and requested more data

** Capricor says it has addressed all manufacturing-related issues

** As of last close, stock down 55% YTD